These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 17196157)

  • 1. Removal of C-ring from the CD-ring skeleton of 1alpha,25-dihydroxyvitamin D3 does not alter its target tissue metabolism significantly.
    Reddy GS; Robinson M; Wang G; Palmore GT; Gennaro L; Vouros P; De Clercq P; Vandewalle M; Young W; Ling S; Verstuyf A; Bouillon R
    Arch Biochem Biophys; 2007 Apr; 460(2):254-61. PubMed ID: 17196157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3 and 1alpha,25-dihydroxy-16-ene-23-yne-20-epi-vitamin D3: analogs of 1alpha,25-dihydroxyvitamin D3 that resist metabolism through the C-24 oxidation pathway are metabolized through the C-3 epimerization pathway.
    Reddy GS; Rao DS; Siu-Caldera ML; Astecker N; Weiskopf A; Vouros P; Sasso GJ; Manchand PS; Uskokovic MR
    Arch Biochem Biophys; 2000 Nov; 383(2):197-205. PubMed ID: 11185554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue specific metabolism of 1alpha,25-dihydroxy-20-epi-vitamin D3 into new metabolites with significant biological activity: studies in rat osteosarcoma cells (UMR 106 and ROS 17/2.8).
    Siu-Caldera ML; Rao DS; Astecker N; Weiskopf A; Vouros P; Konno K; Fujishima T; Takayama H; Peleg S; Reddy GS
    J Cell Biochem; 2001; 82(4):599-609. PubMed ID: 11500938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of 1alpha,25-dihydroxy-3-epi-vitamin D3 in two rat osteosarcoma cell lines (UMR 106 and ROS 17/2.8): existence of the C-3 epimerization pathway in ROS 17/2.8 cells in which the C-24 oxidation pathway is not expressed.
    Siu-Caldera ML; Sekimoto H; Weiskopf A; Vouros P; Muralidharan KR; Okamura WH; Bishop J; Norman AW; Uskoković MR; Schuster I; Reddy GS
    Bone; 1999 May; 24(5):457-63. PubMed ID: 10321905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell specificity and properties of the C-3 epimerization of Vitamin D3 metabolites.
    Kamao M; Tatematsu S; Sawada N; Sakaki T; Hatakeyama S; Kubodera N; Okano T
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):39-42. PubMed ID: 15225744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of 2-methyl analogs of 1alpha,25-dihydroxyvitamin D3 in rat osteosarcoma cells (UMR 106).
    Sunita Rao D; Siu-Caldera ML; Sekimoto H; Gennaro L; Vouros P; Takayama H; Konno K; Fujishima T; Reddy GS
    Biol Pharm Bull; 2002 Jul; 25(7):845-52. PubMed ID: 12132655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and identification of 1alpha-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion.
    Brown AJ; Ritter CS; Weiskopf AS; Vouros P; Sasso GJ; Uskokovic MR; Wang G; Reddy GS
    J Cell Biochem; 2005 Oct; 96(3):569-78. PubMed ID: 16088954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion.
    Brown AJ; Ritter C; Slatopolsky E; Muralidharan KR; Okamura WH; Reddy GS
    J Cell Biochem; 1999 Apr; 73(1):106-13. PubMed ID: 10088729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological activity of CD-ring modified 1alpha,25-dihydroxyvitamin D analogues: C-ring and five-membered D-ring analogues.
    Verstuyf A; Verlinden L; van Etten E; Shi L; Wu Y; D'Halleweyn C; Van Haver D; Zhu GD; Chen YJ; Zhou X; Haussler MR; De Clercq P; Vandewalle M; Van Baelen H; Mathieu C; Bouillon R
    J Bone Miner Res; 2000 Feb; 15(2):237-52. PubMed ID: 10703925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-25 hydroxylation of 1alpha,24(R)-dihydroxyvitamin D3 is catalyzed by 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1): metabolism studies with human keratinocytes and rat recombinant CYP24A1.
    Astecker N; Bobrovnikova EA; Omdahl JL; Gennaro L; Vouros P; Schuster I; Uskokovic MR; Ishizuka S; Wang G; Reddy GS
    Arch Biochem Biophys; 2004 Nov; 431(2):261-70. PubMed ID: 15488475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and metabolic studies of 1α,2α,25-, 1α,4α,25- and 1α,4β,25-trihydroxyvitamin D3.
    Takano M; Sawada D; Yasuda K; Nishikawa M; Takeuchi A; Takagi K; Horie K; Reddy GS; Chen TC; Sakaki T; Kittaka A
    J Steroid Biochem Mol Biol; 2015 Apr; 148():34-7. PubMed ID: 25263656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog.
    Aparna R; Subhashini J; Roy KR; Reddy GS; Robinson M; Uskokovic MR; Venkateswara Reddy G; Reddanna P
    J Cell Biochem; 2008 Aug; 104(5):1832-42. PubMed ID: 18348265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybrid structural analogues of 1,25-(OH)2D3 regulate chondrocyte proliferation and proteoglycan production as well as protein kinase C through a nongenomic pathway.
    Boyan BD; Posner GH; Greising DM; White MC; Sylvia VL; Dean DD; Schwartz Z
    J Cell Biochem; 1997 Sep; 66(4):457-70. PubMed ID: 9282324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly active analogs of 1alpha,25-dihydroxyvitamin D(3) that resist metabolism through C-24 oxidation and C-3 epimerization pathways.
    Uskokovic MR; Norman AW; Manchand PS; Studzinski GP; Campbell MJ; Koeffler HP; Takeuchi A; Siu-Caldera ML; Rao DS; Reddy GS
    Steroids; 2001; 66(3-5):463-71. PubMed ID: 11179755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
    Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
    Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of all possible A-ring diastereomers at the 1- and 3-positions of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (ED-71) using C2-symmetrical epoxide as a common starting material.
    Kubodera N; Hatakeyama S
    Anticancer Res; 2009 Sep; 29(9):3571-8. PubMed ID: 19667150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and identification of 1alpha-hydroxy-24-oxovitamin D3 and 1alpha,23-dihydroxy-24-oxovitamin D3: metabolites of 1alpha,24(R)-dihydroxyvitamin D3 produced in rat kidney.
    Weinstein EA; Rao DS; Siu-Caldera ML; Tserng KY; Uskokovic MR; Ishizuka S; Reddy GS
    Biochem Pharmacol; 1999 Dec; 58(12):1965-73. PubMed ID: 10591152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biological activity of nonsteroidal vitamin D hormone analogs lacking both the C- and D-rings.
    Verstuyf A; Verlinden L; Van Baelen H; Sabbe K; D'Hallewyn C; De Clercq P; Vandewalle M; Bouillon R
    J Bone Miner Res; 1998 Apr; 13(4):549-58. PubMed ID: 9556055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetric catalytic ene-cyclization approach to 2-fluoro-19-nor-1,25-dihydroxyvitamin D(3) A-ring analog with significant transactivation activity.
    Mikami K; Ohba S; Ohmura H; Kubodera N; Nakagawa K; Okano T
    Chirality; 2001 Jul; 13(7):366-71. PubMed ID: 11400190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.